Natixis Advisors LLC Buys 11,726 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Natixis Advisors LLC raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 8.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 153,717 shares of the company’s stock after purchasing an additional 11,726 shares during the period. Natixis Advisors LLC’s holdings in Roivant Sciences were worth $1,774,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Rubric Capital Management LP lifted its stake in shares of Roivant Sciences by 15.0% in the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after buying an additional 3,000,000 shares during the period. Troluce Capital Advisors LLC bought a new stake in shares of Roivant Sciences in the 2nd quarter worth approximately $31,182,000. BlackBarn Capital Partners LP lifted its position in shares of Roivant Sciences by 63.1% in the 2nd quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock worth $32,767,000 after acquiring an additional 1,199,406 shares during the period. Vanguard Group Inc. grew its holdings in shares of Roivant Sciences by 14.6% during the 1st quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock worth $85,441,000 after purchasing an additional 1,030,681 shares in the last quarter. Finally, Sofinnova Investments Inc. increased its position in shares of Roivant Sciences by 86.5% during the second quarter. Sofinnova Investments Inc. now owns 1,868,412 shares of the company’s stock valued at $19,749,000 after purchasing an additional 866,708 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Trading Down 0.6 %

Shares of Roivant Sciences stock opened at $12.46 on Tuesday. The stock has a market capitalization of $9.07 billion, a price-to-earnings ratio of 2.22 and a beta of 1.24. The firm’s 50-day moving average price is $11.69 and its two-hundred day moving average price is $11.33. Roivant Sciences Ltd. has a 1-year low of $8.61 and a 1-year high of $13.06.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Financial Lp Qvt sold 876,000 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the transaction, the director now owns 22,179,358 shares of the company’s stock, valued at approximately $262,160,011.56. This represents a 3.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the completion of the sale, the chief accounting officer now directly owns 209,322 shares of the company’s stock, valued at $2,488,838.58. This trade represents a 54.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,677,309 shares of company stock valued at $43,283,184 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. Finally, Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and an average price target of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.